Financiere de TubizeMIL:1TUB 16 Return-on-Tangible-Equity is -0.25% as of Dec. 2025. GuruFocus rates MIL:1TUB with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 1,197 Biotechnology companies, Financiere de Tubize ranks better than 81.95% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Financiere de Tubize's annualized net income for the quarter that ended in Dec. 2025 was €-4.69 Mil. Financiere de Tubize's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €1,910.77 Mil. Therefore, Financiere de Tubize's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -0.25%.
The historical rank and industry rank for Financiere de Tubize's Return-on-Tangible-Equity or its related term are showing as below:
MIL:1TUB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.72 Med: 7.14 Max: 14.04
Current: 4.94
During the past 13 years, Financiere de Tubize's highest Return-on-Tangible-Equity was 14.04%. The lowest was 3.72%. And the median was 7.14%.
MIL:1TUB's Return-on-Tangible-Equity is ranked better than 81.95% of 1197
companies
in the Biotechnology industry
Industry Median: -42.4
vs MIL:1TUB: 4.94
Financiere de Tubize (MIL:1TUB) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Financiere de Tubize Return-on-Tangible-Equity Related Terms
Financiere de Tubize Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Financiere de Tubize's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Financiere de Tubize Return-on-Tangible-Equity Chart
MIL:1TUB vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Financiere de Tubize's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Financiere de Tubize Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Financiere de Tubize's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Financiere de Tubize's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -0.25% mean?
Financiere de Tubize (MIL:1TUB) has a Return-on-Tangible-Equity of -0.25% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Financiere de Tubize and its competitors. Over the past decade, Financiere de Tubize's Return-on-Tangible-Equity has ranged from 3.72 to 14.04. According to the industry distribution chart, Financiere de Tubize ranks #216 out of 1197 companies in the Biotechnology industry, placing it in the top 18%.
Is Financiere de Tubize's Return-on-Tangible-Equity too high?
Financiere de Tubize's current Return-on-Tangible-Equity is -0.25%. Over the past 10 years, this metric has ranged from a low of 3.72 to a high of 14.04. Based on the distribution chart, Financiere de Tubize ranks #216 out of 1197 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Financiere de Tubize has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Financiere de Tubize's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Financiere de Tubize ranks #216 out of 1197 companies for Return-on-Tangible-Equity. This places Financiere de Tubize in the top 18% of its industry — outperforming the majority of peers. Historically, Financiere de Tubize's own Return-on-Tangible-Equity has ranged from 3.72 to 14.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Financiere de Tubize and its competitors. Financiere de Tubize's current Return-on-Tangible-Equity is -0.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Financiere de Tubize stock overvalued right now?
Financiere de Tubize (MIL:1TUB) has a current Return-on-Tangible-Equity of -0.25%. The current Return-on-Tangible-Equity is -0.25%. Financiere de Tubize's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Financiere de Tubize (MIL:1TUB), the current Return-on-Tangible-Equity is -0.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a world-wide biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Majority of its sales revenue is derived from its neurology products, followed by its immunology products. The company's plan focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
16GF Score
Get the complete analysis for MIL:1TUB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1TUB has been successfully added to your 
